Physician profile
Karl Lee
NPI 1093746703
$7,967.81
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,156 · 2020: $2,164 · 2021: $2,840 · 2022: $1,786 · 2024: $21.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,681.96 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,200.70 | 2019-2022 | |
| Gilead Sciences, INC. | $651.76 | 2019-2022 | |
| Lilly USA, LLC | $590.56 | 2019-2022 | |
| Novo Nordisk INC | $584.94 | 2019-2022 | |
| Pfizer INC. | $542.80 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.79 | 2020-2022 | |
| Amgen INC. | $318.10 | 2021-2022 | |
| Amarin Pharma, INC. | $269.48 | 2020-2021 | |
| Glaxosmithkline, LLC. | $269.07 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $222.73 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $207.72 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $200.66 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $165.48 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $104.05 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $90.16 | 2022 | |
| Allergan, INC. | $85.07 | 2020 | |
| Abbvie INC. | $65.57 | 2021 | |
| Astellas Pharma US INC | $54.32 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $49.00 | 2019 | |
| Esperion Therapeutics, INC. | $44.38 | 2020 | |
| Snap Diagnostics LLC | $30.33 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $24.35 | 2021 | |
| Kedrion Biopharma, INC. | $21.64 | 2024 | Rhogam Ultra-Filtered Plus, Gammaked, Albuked |
| Novartis Pharmaceuticals Corporation | $20.02 | 2019 | |
| Endo Pharmaceuticals INC. | $16.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.